ClinicalTrials.gg
RecruitingNCT06864741Updated Mar 18, 2026

Virtual Reality Rehabilitation for Stroke Patients in the Hospital and at Home.

An interventional study of Virtual reality guided motor rehabilitation in Stroke Acute, sponsored by Nova Scotia Health Authority. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Nova Scotia Health Authority · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Stroke by Nova Scotia Health Authority — 5 open to participants now, 5 under way, none of them phase 3. Stroke · Nova Scotia Health Authority.

Planned enrollment
2nd of 11
40 · median 14
Started
2025
with 2 others
No phase
10 of 14
4 open now
Registered
13th of 14
by date

Among the 14 studies in Stroke by Nova Scotia Health Authority, this one is the 2nd largest by planned enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2025, is one of 10 with no phase, and was the 13th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

5 of the 14 studies in Stroke by Nova Scotia Health Authority are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Stroke by Nova Scotia Health Authority, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test whether a low-cost virtual reality (VR) motor rehabilitation platform can improve motor recovery in people recovering from a first-time ischemic stroke both in the hospital and at home. The study focuses on adults aged 18 and older who have experienced moderate to severe upper limb motor deficits.

The main questions it aims to answer are:

  • Can VR-based motor therapy improve upper limb motor function compared to standard care?
  • Is VR-based motor therapy a feasible and acceptable treatment option for stroke patients?

Researchers will compare patients receiving VR therapy to those receiving standard care to see if the VR therapy leads to greater improvements in motor recovery and more positive patient experiences.

Participants will:

  • Complete standardized assessments of motor function and quality of life at multiple time points.
  • Participate in VR therapy sessions (if in the treatment group), using gamified activities designed to improve upper limb movement.
  • Provide feedback on their experience with the VR system, including ease of use, motion sickness, and engagement.

This study will help determine whether VR-based rehabilitation can be a practical, effective way to improve access to therapy and recovery outcomes for stroke patients, especially in rural settings with limited rehabilitation resources.

03

Conditions studied

  • Stroke Acute

Keywords

  • stroke
  • rehabilitation
  • motor disorder
  • virtual reality
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • clinical diagnosis of first-time ischemic stroke involving the middle cerebral artery, confirmed by CT or MRI;
  • score between 6 and 40 on Fugl-Meyer Assessment's Upper Limb Extremity Subscore (FM - UE), indicating moderate to severe motor deficit;
  • ability and willingness to provide consent (score of 18 or more on the ) or assent (for scores lower than 18 on MoCA with consent provided by an authorized third party with the necessary legal authority to consent on behalf of patient)
  • INPATIENT ARM: less than 5 weeks since stroke onset with admission to Valley Regional Hospital in Kentville, NS, Canada
  • OUTPATIENT ARM: less than 3 months since stroke onset with discharge to home setting located within 1 hour drive of Valley Regional Hospital in Kentville, NS, Canada

Exclusion criteria

Exclusion Criteria:

  • brainstem, cerebellar or bilateral stroke lesion
  • a secondary neurological condition (e.g., Parkinson's disease)
  • musculoskeletal injuries interfering with task performance
  • an uncorrected visual deficit due to stroke or other etiologies
  • apraxia as identified by clinical assessment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • No intervention
    In Hospital - Standard of Care

    Inpatient standard of care for acute stroke

  • Experimental
    In Hospital - Virtual Reality Rehabilitation

    Inpatient supplementary rehabilitation delivered through a virtual reality headset

    Behavioral: Virtual reality guided motor rehabilitation

  • No intervention
    At Home - Standard of care

    Outpatient standard of care for acute stroke

  • Experimental
    At Home - Virtual Reality Rehabilitation

    Outpatient supplementary rehabilitation delivered through a virtual reality headset

    Behavioral: Virtual reality guided motor rehabilitation

Interventions

  • BehavioralVirtual reality guided motor rehabilitation

    Custom rehabilitation exercises running on a Meta Quest 2/3S/3 head mounted virtual reality display.

06

What researchers measure

Primary outcomes

  1. Treatment effectiveness in hospital

    Measure if patients receiving supplementary VR motor therapy show improved motor recovery compared to receiving standard care in hospital using the Fugl-Meyer Assessment's Upper Limb Extremity Subscore. Values range from 0 to 66 with lower scores indicating a larger motor deficit.

    Time frame: From enrollment to one week following the end of treatment at day 26

  2. Treatment effectiveness at home

    Measure if patients receiving supplementary VR motor therapy show improved motor recovery compared to receiving standard care for home-based patients using the Fugl-Meyer Assessment's Upper Limb Extremity Subscore. Values range from 0 to 100 with lower scores indicating a larger motor deficit.

    Time frame: From enrollment through standard of care and VR treatment completion on Day 47

  3. Treatment feasibility - Motion Sickness

    Measure motion sickness levels immediately after each therapy sessions using the Virtual Reality Sickness Questionnaire. Values range from 0 to 100 with higher scores indicating more reported motion sickness.

    Time frame: From enrollment to one week following the end of treatment

  4. Treatment feasibility - Attitudes towards technology

    Measure attitudes towards the VR technology before and after the intervention using a VR Attitudes Survey. Values range from 0 to 6 with higher scores indicating more favorable attitudes towards the VR technology.

    Time frame: From enrollment to one week following the end of treatment

  5. Patient engagement at home

    Assess patient engagement with adaptive at-home rehabilitation using the percentage of daily sessions completed. Values range from 0% to 100% with higher scores indicating a higher rate of session completion.

    Time frame: From enrollment through standard of care and VR treatment completion on Day 47

Secondary outcomes

  1. Treatment effectiveness - Motor performance

    Measure if patients receiving VR motor therapy show improved motor performance using the Box and Blocks Test. Values range from 0 to 150 with higher scores indicating improved motor performance.

    Time frame: From enrollment to one week following the end of treatment

  2. Treatment effectiveness - Quality of life

    Measure if patients receiving VR motor therapy show reduced disability and improved health-related quality of life using the Stroke Impact Scale. Values range from 0 to 100 with higher scores indicating reduced disability and higher quality of life.

    Time frame: From enrollment to one week following the end of treatment

  3. VR motor assessment validity

    Examine the validity of a VR motor assessment for monitoring stroke motor recovery trajectories in the real world. This will be explored by comparing data between the real-world and virtual Box and Blocks tests which will result in a correlation coefficient ranging from 0 to 1 with a higher value indicating a stronger alignment in metrics.

    Time frame: From enrollment to one week following the end of treatment

  4. Gender differences in acceptance of VR rehabilitation technology

    Analyze differences between women and men in relation to the acceptance of VR treatment, using the VR Attitudes Survey. Values range from 0 to 6 with higher scores indicating more favorable attitudes towards the VR technology.

    Time frame: From enrollment to one week following the end of treatment

  5. Independent use of home-based VR treatment

    By meeting certain criteria during the study, participants can qualify to complete VR sessions on their own. Measure the proportion of participants qualifying for independent operation.

    Time frame: From enrollment through standard of care and VR treatment completion on Day 47

  6. Performance characteristics of stroke patients

    Measure motor performance for each task over time using motor performance z-scores. Mean scores equal zero with deviations indicating distance in standard deviations from the mean (with no minimum or maximum). Higher scores indicate better motor performance.

    Time frame: From enrollment to last VR rehabilitation session

  7. Barriers to treatment adoption

    Qualitative feedback will be analyzed thematically to identify potential barriers and enablers of adopting VR stroke rehabilitation. This qualitative analysis does not use a quantitative scale.

    Time frame: From enrollment to one week following the last VR session

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Given the small sample size and single recruitment site, the investigators are uncertain if confidentiality can be ensured with sharing IPD. The investigators will address this with the institution's Research Ethics Board.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jun 2027, 20 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 20 months is below that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2025
First posted
Mar 7, 2025
StartActual
Oct 15, 2025
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06864741
Collaborators
Acadia University
Responsible party
Sponsor
First posted
Mar 7, 2025
Start date
Oct 15, 2025
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Mar 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion